Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1/NF-κB Signaling Pathway

• Päätekijät: Jian-ning Zhang (Tekijä), Yang Ma (Tekijä), Xi-yan Wei (Tekijä), Ke-yin Liu (Tekijä), Hao Wang (Tekijä), Hui Han (Tekijä), Yi Cui (Tekijä), Ming-xiang Zhang (Tekijä), Wei-dong Qin (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Hindawi Limited, 2019-01-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Sepsis is a leading cause of death in patients with severe infection worldwide. Remifentanil is an ultra-short-acting, potent opioid analgesic. In the study, we aimed to investigate the role and underlying mechanism of remifentanil in lipopolysaccharide- (LPS-) induced inflammation in human aortic e...